title: [Comparison of immune reconstitution at early stage after unmanipulated haploidentical stem cell transplantation between high- and standard- risk Philadelphia chromosome- negative acute lymphoblastic leukemia patients in CR1].
abstract: OBJECTIVE
  To compare the early stage immune reconstitution of high- and standard-risk Philadelphia chromosome- negative acute lymphoblastic leukemia (ALL) CR1 patients who had haploidentical blood and marrow stem cell transplantation (HBMT).
  
  
  METHODS
  A total of 49 Ph-negative ALL CR1 patients who received HBMT and had complete early stage immune reconstitution data(+30, +60 and +90 d post transplantation) from Jan. 2010 to Dec. 2012 were enrolled. Immunophenotyping for B and T lymphocytes was performed post HBMT via flow cytometry. Fresh peripheral blood cells were stained with fluorochrome-labeled monoclonal antibodies against cluster of differentiation CD19, CD3, CD4, CD8, CD45RO, CD45RA and CD28. The early reconstitution of lymphocyte subsets, survival and prognosis between standard- risk group, high- risk adult group and high- risk children group were compared.
  
  
  RESULTS
  There were no significant differences in all these T lymphocyte subsets among three groups at the three check points (P>0.05). Moreover, at the same time, comparable outcome had been achieved between standard-risk group (n=18), high-risk adult group (n=16) and high-risk children group (n=15). There were no differences in 2- y relapse incidence (27.8% vs 31.3% vs 26.7%, P=0.957), 2- y non- relapse mortality (11.1% vs 0 vs 13.3%, P=0.185), 2- y leukemia free survival (61.1% vs 68.8% vs 60.0%, P=0.834) and overall survival (77.8% vs 68.8% vs 60.0%, P=0.529) among the three groups. Incidence of grade Ⅱ-Ⅳ aGVHD was 44.4% vs 12.5% vs 46.7% (P=0.075) and incidence of cGVHD was 61.1% vs 50.0% vs 40.0% (P=0.249).
  
  
  CONCLUSIONS
  Comparison of immune reconstitution at early stage may be a reasonable cause to explain that equivalent outcomes were observed among high- and standard- risk Ph- negative ALL CR1 patients after HBMT.
authors: Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases, Beijing 100044, China.
authors: Z L
authors: ZL
authors: Bian
authors: Y J
authors: YJ
authors: Chang
authors: L P
authors: LP
authors: Xu
authors: Y
authors: Y
authors: Wang
authors: X H
authors: XH
authors: Zhang
authors: K Y
authors: KY
authors: Liu
authors: X J
authors: XJ
authors: Huang
mesh_terms: D000208:Acute Disease; D000328:Adult; D002648:Child; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D016130:Immunophenotyping; D008214:Lymphocytes; D036102:Peripheral Blood Stem Cell Transplantation; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics* / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence